An 81-year-old right-handed man reported 3 years of progressive language-predominant cognitive difficulty (word-finding, losing train of thought). MoCA 23/30 with naming/word-finding deficits; comprehension intact. MRI showed advanced deep white-matter ischemic disease and multiple lobar/cortical microhemorrhages consistent with CAA. FDG-PET demonstrated abnormal cortical metabolism. Neuropsychology (2021–2025) progressed from mild neurocognitive disorder to multi-domain impairment (executive, language, memory, visuospatial). Brief positive sensory–motor spells were judged CAA-related TFNEs. For 10 years the speech phenomenon had been labeled “vocal tics.” ENT/swallow were normal; EMG and myasthenia testing were negative; routine and extended EEG were unremarkable. Bedside exam captured speech-triggered platysma myoclonus causing transient speech arrest. Levetiracetam 250 mg nightly, later 125 mg at bedtime for vivid dreams, produced marked reduction in spasms by patient report and examiner observation; mild dizziness only. Memantine was tolerated at 15 mg/day; rivastigmine was not. The patient remained independent in basic activities and continued to drive.